SRI-37330 HCl(EX-A5854), an anti-diabetic drug, is an orally bioavailable inhibitor of thioredoxin-interacting protein (TXNIP), with an IC50 of 0.64 μM for TXNIP expression in INS-1 cells. Its treatment inhibits glucagon secretion and function, decreases hepatic glucose production, and reverses hepatic steatosis.

SRI-37330 HCl(EX-A5854), an anti-diabetic drug, is an orally bioavailable inhibitor of thioredoxin-interacting protein (TXNIP), with an IC50 of 0.64 μM for TXNIP expression in INS-1 cells. Its treatment inhibits glucagon secretion and function, decreases hepatic glucose production, and reverses hepatic steatosis.

Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

A-484954 is a highly selective eukaryotic elongationfactor-2 kinase(eEF2K) inhibitor, with an IC50 of 280 nM.

Zunsemetinib(ATI-450, CDD-450) is a selective inhibitor of p38α mitogen-activated protein kinase-activated protein kinase 2 (MK2) that mediates inflammatory responses. It reduces inflammation in cryopyrinopathy, alleviates arthritis, and potentially prevents tachyphylaxis.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.

VIT-2763 is an oral small-molecule inhibitor of ferroportin. It displaces TMR-hepcidin from ferroportin with an IC50 of 24 nM. It also ameliorates anemia, enhances erythropoiesis, and reduces organ iron loading in the Hbbth3/+ β-thalassemia intermedia disease model.